RIVA-PREGABALIN 225 MG
PREGABALIN : 225 MG · DIN 02404133 · LABORATOIRE RIVA INC.
Health Canada status: APPROVED
What is RIVA-PREGABALIN?
RIVA-PREGABALIN 225 MG contains PREGABALIN : 225 MG. It is listed in the Health Canada Drug Product Database under DIN 02404133, held by LABORATOIRE RIVA INC., supplied as CAPSULE for ORAL administration. Health Canada currently lists it as approved, status dated 16-Apr-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is RIVA-PREGABALIN used for?
Management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, spinal cord injury, and management of pain associated with fibromyalgia.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02404133 |
|---|---|
| Brand name | RIVA-PREGABALIN |
| Generic / active ingredient | PREGABALIN : 225 MG |
| Manufacturer | LABORATOIRE RIVA INC. |
| Strength | 225 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N02BF02 PREGABALIN |
| AHFS class | 28:12.92 |
| Biosimilar | No |
| Health Canada status | APPROVED |
| Status date | 16-Apr-2013 |
How is it administered?
Starting dose 150 mg/day (BID or TID). May increase to 300 mg/day after 1 week. Max 600 mg/day. Taper gradually over at least 1 week when discontinuing. Adjust dose for renal impairment.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided text snippet (refer to section 11), but typically 15-30°C for similar products.
How is it supplied?
HDPE bottles of 100, 500, 800, 1000, or 1400 capsules depending on strength.
Contraindications
Hypersensitivity to pregabalin or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container.
Warnings and precautions
Serious Warning: Life-threatening respiratory depression when used with opioids. Risk of angioedema, hypersensitivity, suicidal ideation, dizziness, somnolence, and peripheral edema.
Is PREGABALIN in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N02BF02 PREGABALIN. 108 of 271 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACH-PREGABALIN | 150 MG | CAPSULE | ACCORD HEALTHCARE INC | MARKETED | DIN 02449870 |
| ACH-PREGABALIN | 225 MG | CAPSULE | ACCORD HEALTHCARE INC | MARKETED | DIN 02449897 |
| ACH-PREGABALIN | 25 MG | CAPSULE | ACCORD HEALTHCARE INC | MARKETED | DIN 02449838 |
| ACH-PREGABALIN | 300 MG | CAPSULE | ACCORD HEALTHCARE INC | MARKETED | DIN 02449900 |
| ACH-PREGABALIN | 50 MG | CAPSULE | ACCORD HEALTHCARE INC | MARKETED | DIN 02449846 |
| ACH-PREGABALIN | 75 MG | CAPSULE | ACCORD HEALTHCARE INC | MARKETED | DIN 02449854 |
| AG-PREGABALIN | 150 MG | CAPSULE | ANGITA PHARMA INC. | MARKETED | DIN 02480751 |
| AG-PREGABALIN | 25 MG | CAPSULE | ANGITA PHARMA INC. | MARKETED | DIN 02480727 |
| AG-PREGABALIN | 300 MG | CAPSULE | ANGITA PHARMA INC. | MARKETED | DIN 02480778 |
| AG-PREGABALIN | 50 MG | CAPSULE | ANGITA PHARMA INC. | MARKETED | DIN 02480735 |
Who else supplies PREGABALIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. PREGABALIN appears in 1034 registered pack listings across 13 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.